PCYC-1145-LT: This is a protocol that provides continued access to ibrutinib for people who have benefited from ibrutinib in prior clinical trialsExtended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials

Trial purpose

Cancer treatment

Tumor type

Multi-Cancer

Age

18+

Trial acronym

PCYC-1145-LT

Summary

This study is recruiting by invitation only, and aims to provide continued access to Ibrutinib to people who have completed parent Ibrutinib studies, are still benefitting from treatment with Ibrutinib, and have no access to commercial Ibrutinib for their underlying disease within their region.

People enrolled in this treatment protocol will receive oral continuous dosing with Ibrutinib at the same dose and schedule they were receiving at the end of the respective parent study. Treatment may be continued as long as the participants continue to derive benefit from treatment with Ibrutinib until such time that Ibrutinib becomes commercially available for the indication of the parent study.

Conditions

This trial is treating people with solid cancers, B-cell lymphoma, non-Hodgkin lymphoma, B-cell leukaemia or Graft vs Host Disease who have previously participated in an Ibrutinib clinical trial

No longer recruiting (closed or complete) hospitals